In addition, our results showed that AS-IV treatment significantly reduced the expression of inflammatory factors TGF-β and IL-11 closely associated with pulmonary fibrosis, which is consistent with previous studies44. This evidence concerns the gene IL11 and pulmonary fibrosis.